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publication, The apparcutiy contradictory findings between our study 
and that of others are potentially rcconcdablc when one appreciates 
that patients with ST.segmcnt depression in the LATE study had at 
,least 2 mm-of ST depression. This group was not specifically addressed 
within the Thrombolysis in Myocardial Infarction 111 study (2) (tem- 
poral window U to IT h vs. 6 to 2J h in the LATE studv). Morcovcr, the 
natural history studies of Lee rt al. (3) have demonstrated that more 
prominent ST segment depression (i.c,.. 22 mm) is highly specific for 
the subsequent diagnosis of acute myocardial infarction and is also an 
indicator of increased risk. It is important to clarity that this group of 
patients did not have unusually prolonged pain but a prolonged time 
from the onset of pain to clinical presentation (i.e.. >6 h). 
We were careful to address obvious limitations of our study in the 
original manuscript and, in particular. did not advocate a change in the 
current thrombolytic therapy algorithm for acute myocardial infarc- 
tion. We remain convinced, however. that some patients with signifi- 
cant ST segment depression may benefit from thrombolytic therapy 
and are pleased that Anderson shares our interest in the need for 
prospective validation. 
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Basal Nitric Oxide Production by Diseased 
Coronary Arteries 
Egashira et al. (I) in their interesting study examined the effects of 
intracoronaty N”-monomethyl-L-arginine (LNMMA. ti inhibitor of 
nitric oxide synthesis) on basal coronary artery tone in Patients with 
variant angina and normal curonary arteries and in control subject 
They reported that tk comtrktor response to LNMMA was signiti- 
that 
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at the non$paslic sites. Their results indicate that the hasal rclrase of 
nitric oxidcis incrcascd rather than decreased at the spastic site in 
patients with variant angina. The authors did not examine the effect of 
atheroma on basal nitric oxide production. hut they acknowledge this 
limitation. This limitation is particularly relevant because many pa- 
tients with spasm have underlying atheroma. 
WC recently examined (2.3) the effects of an intracoronaty infusion 
of LNMMA in patients with chronic stable angina and coronary artcty 
discasc and in patienis with normal coronary arteriograms. The 
diameter of angiographically normal proximal and distal segments and 
coronary sttnoscs was measured by quantitative angiography. In 
response to an LNMMA infusion of 16 pmol’min for 4 min. there was 
a significant reduction (p < 0.01) in lumen diameter of the distal 
segments of diseased arteries and at the site of stenosis but no change 
(p = NS) in lumen diameter of the proximal segments (3). In patients 
with normal coronary artetiograms. there was a significant reduction 
(p < 0.01) in lumen diameter of both proximal and distal segments (2). 
These results indicate that basal nitric oxide production is pre- 
served at the site of stenotic atheromatous plaques. Because it appears 
to be absent in the proximal segments of diseased arteries in which the 
stenoses were mostly located, it is possible that regeneration of basal 
nitric oxide product& has occurred. There is some laboratory evi- 
dence ~osupport this hypothesis because the inducible isoform of nitric 
oxide synrhasc has been found in human atherosclerotic lesions ex 
\ ivo. where it is localized with macrophages. foam cells and vascular 
smooth muscle cells (4). Furthermore. the amount of nitric oxide 
synthase present is related to the severity of the lesion. WC therefore 
propose that atherosclerotic coronary arteries can regenerate basal 
uitric oxide production from an abnormal source. 
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release of nitric oxide (NO) is altered at site of spasm in pltients with 
